Neurosense Therapeutics Stock Probability of Future Stock Price Finishing Under 0.81
| NRSN Stock | USD 0.93 0.02 2.20% |
Neurosense |
Neurosense Therapeutics Target Price Odds to finish below 0.81
The tendency of Neurosense Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.81 or more in 90 days |
| 0.93 | 90 days | 0.81 | near 1 |
Based on a normal probability distribution, the odds of Neurosense Therapeutics to drop to $ 0.81 or more in 90 days from now is near 1 (This Neurosense Therapeutics probability density function shows the probability of Neurosense Stock to fall within a particular range of prices over 90 days) . Probability of Neurosense Therapeutics price to stay between $ 0.81 and its current price of $0.93 at the end of the 90-day period is under 4.
Given the investment horizon of 90 days Neurosense Therapeutics has a beta of -0.57. This indicates as returns on the benchmark increase, returns on holding Neurosense Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Neurosense Therapeutics is likely to outperform the market. Additionally Neurosense Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Neurosense Therapeutics Price Density |
| Price |
Predictive Modules for Neurosense Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Neurosense Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neurosense Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neurosense Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Neurosense Therapeutics is not an exception. The market had few large corrections towards the Neurosense Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Neurosense Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Neurosense Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.26 | |
β | Beta against Dow Jones | -0.57 | |
σ | Overall volatility | 0.14 | |
Ir | Information ratio | -0.09 |
Neurosense Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Neurosense Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Neurosense Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Neurosense Therapeutics generated a negative expected return over the last 90 days | |
| Neurosense Therapeutics has some characteristics of a very speculative penny stock | |
| Neurosense Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurosense Therapeutics currently holds about 10.37 M in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Neurosense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 35.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Financial Analysis Emmaus Life Sciences versus NeuroSense Therapeutics |
Neurosense Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Neurosense Stock often depends not only on the future outlook of the current and potential Neurosense Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neurosense Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 13.6 M | |
| Cash And Short Term Investments | 2.6 M |
Neurosense Therapeutics Technical Analysis
Neurosense Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Neurosense Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Neurosense Therapeutics. In general, you should focus on analyzing Neurosense Stock price patterns and their correlations with different microeconomic environments and drivers.
Neurosense Therapeutics Predictive Forecast Models
Neurosense Therapeutics' time-series forecasting models is one of many Neurosense Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Neurosense Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Neurosense Therapeutics
Checking the ongoing alerts about Neurosense Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Neurosense Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Neurosense Therapeutics generated a negative expected return over the last 90 days | |
| Neurosense Therapeutics has some characteristics of a very speculative penny stock | |
| Neurosense Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurosense Therapeutics currently holds about 10.37 M in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Neurosense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 35.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Financial Analysis Emmaus Life Sciences versus NeuroSense Therapeutics |
Check out Neurosense Therapeutics Backtesting, Neurosense Therapeutics Valuation, Neurosense Therapeutics Correlation, Neurosense Therapeutics Hype Analysis, Neurosense Therapeutics Volatility, Neurosense Therapeutics History as well as Neurosense Therapeutics Performance. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.